Hot Keywords
non-alcoholic fatty liver disease epidemiology microenvironment nonalcoholic steatohepatitis transplantation cholangiocarcinoma direct-acting antiviral immunotherapy hepatitis B hepatitis C liver resection imaging cancer stem cell diagnosis gene cirrhosis biomarker recurrence

Topic: Molecular Pathogenesis and Drivers of Cholangiocarcinoma

A special issue of Hepatoma Research

ISSN 2454-2520 (Online), ISSN 2394-5079 (Print)

Submission deadline: 30 Dec 2022

Guest Editor(s)

  • Luca Fabris, MD, PhD
    Associate Professor of Gastroenterology, Department of Molecular Medicine, University of Padova, Padua, Italy.

    Website | E-mail

  • Diego F. Calvisi, MD
    Associate Professor of Department of Medical, Surgical and Experimental Medicine, University of Sassari, Sassari, Italy.

    Website | E-mail

Special Issue Introduction

Development and progression of cholangiocarcinoma (CCA) is sustained by an intricate and heterogeneous process that include the deregulation of signalling pathways, related to development and liver repair, which control cell homeostasis and survival, chronic inflammation, fibrosis, angiogenesis and immune cell response. A complex interplay of extracellular ligands (pro-inflammatory cytokines and chemokines, growth factors, matrix components among others) released by a multitude of cell types which populate a dense tumour microenvironment represents a defining feature of CCA. Moreover, thanks to the advent of integrative genomic studies, it is emerging that distinctive genomic alteration affecting cell cycle regulation, DNA damage and repair, kinase signalling and morphogens can be differently found in the intrahepatic and extrahepatic variants of CCA (iCCA, eCCA). Moreover, epigenetics, including deregulation of methylation, histone modifications, aberrant expression of non-coding RNAs and post-translation modifications of proteins, was shown to play a key role in either the initiation or progression of CCA. Acquisition of a cancer stem cell-like phenotype may also contribute to the wide tumour heterogeneity and resistance to anti-cancer drugs, which typically characterize CCA.

In this special issue of Hepatoma Research, major experts in the subject will discuss the intricate landscape of genetic and epigenetic perturbations, multicellular communications within the tumour microenvironment, molecular effectors and related signalling, which incite the malignant transformation and the highly invasive behaviour of this still enigmatic type of cancer.

Potential topics include, but are not limited to the followings:
1.Genomic alterations in iCCA
2.Genomic alterations in eCCA
3.Epigenetic alterations and post-translational modifications in CCAs
4.Signalling and molecular networks related to development and inflammation involved in CCA initiation and progression
5.Stemness and plasticity in CCA development and progression
6.Tumor microenvironment highlighting CAF, including different subpopulations
7.Tumor microenvironment highlighting TAM and immune cells
8.Tumor microenvironment highlighting angiogenesis
9.Tumor microenvironment highlighting fibrosis and ECM proteins
10. Chemoresistance and CCA progression


1. Massimiliano Cadamuro Department of Molecular Medicine (DMM), University of Padua, Padua, Italy.
2. Antonio Cigliano Department of Medical, Surgical and Experimental Sciences, University of Sassari, Sassari, Italy.
3. Daniela Sia Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
4. Laura Fouassier Sorbonne Université, Inserm, Centre de Recherche Saint-Antoine, Paris, France.
5. Stefania Cannito Department of Clinical and Biological Sciences, University of Turin, 10125 Turin, Italy.
6. Alessandra Gentilini Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
7. Erica Villa Gastroenterology Unit, Department of Medical Specialties, University of Modena & Reggio Emilia and Modena University-Hospital, Modena, Italy.
8. Robert Montal Department of Medical Oncology, Arnau de Vilanova University Hospital (HUAV), 25198 Lleida, Spain.
9. Ana Lleo Department of Biomedical Sciences, Humanitas University, Pieve Emanuele 20090, Milan, Italy.
10. Chiara Raggi Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
11. Antonio Benedetti Department of Clinic and Molecular Sciences, Polytechnic University of Marche, Via Tronto 10, 60020, Ancona, Italy.
12. Luca Maroni Department of Clinic and Molecular Sciences, Polytechnic University of Marche, Via Tronto 10, 60020, Ancona, Italy.
13. Carmine Mancone Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy.
14. Alessandra Elvevi Division of Gastroenterology and Center for Autoimmune Liver Diseases, San Gerardo Hospital and Department of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy.
15. Michael H. Nathanson Section of Digestive Diseases, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT 06520-8056, USA.
16. Bangyan L. Stiles Pharmacology and Pharmaceutical Sciences, School of Pharmacy, University of Southern California, Los Angeles, CA, USA.

The list is in no particular order and being updated.

Submission Deadline

30 Dec 2022

Submission Information

Articles of special issue are free of charge for article processing.
For Author Instructions, please refer to
For Online Submission, please login at
Submission Deadline: 30 Dec 2022
Contacts: Delphine Wong, Assistant Editor,

Published Articles

© 2016-2023 OAE Publishing Inc., except certain content provided by third parties